4- (sulfanyl-pyrimidin-4-ylmethyl) -morpholine derivatives and related compounds as GABA receptor ligands for the treatment of anxiety, depression and epilepsy

摘要

The present invention relates to compounds of formula wherein X is -S- or -NH-; RSUP3/SUP/RSUP4 /SUPtogether with the N-atom to which they are attached form a non aromatic 5, 6 or 7 membered ring, which optionally contains in addition to the N-atom one additional heteroatom selected from the group consisting of O, S and N, and wherein the ring is optionally substituted by hydroxy, lower alkyl, lower alkoxy, -NRSUB2/SUB, -CONRSUB2/SUB, -CO-lower alkyl or benzyl; or RSUP3/SUP/RSUP4 /SUPform together with the N-atom to which they are attached a heterocyclic ring system, containing two or three rings and which optionally contains one or two additional heteroatoms selected from the group consisting of N and O and which has no more than 20 carbon atoms; and R, RSUP1/SUP, RSUP2/SUP, and RSUP5 /SUPare as defined herein and to pharmaceutically suitable acid addition salts thereof. It has been found that the compounds of the invention are active on the GABASUBB /SUBreceptor and therefore are useful for the treatment of anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, neuropathic pain and craving associated with cocaine and nicotine, psychosis, panic disorder, posttraumatic stress disorders and gastro-intestinal disorders.